Anti-SARS-CoV-2 Spike RBD Broadly Neutralizing Antibody, Human IgG1 (AM359b) (MALS verified), Unconjugated

Product Overview

• Article Name: Anti-SARS-CoV-2 Spike RBD Broadly Neutralizing Antibody, Human IgG1 (AM359b) (MALS verified), Unconjugated
• Biozol Catalog Number: ABS-SPD-M265-100UG
• Supplier Catalog Number: SPD-M265-100ug
• Alternative Catalog Number: ABS-SPD-M265-100UG
• Manufacturer: AcroBiosystems
• Host: Human
• Category: Antikörper
• Species Reactivity: Human
• Conjugation: Unconjugated

Product Description

The antibody is isolated from the serum of COVID19 vaccine recipient and is recombinantly produced from human 293 cells (HEK293). This antibody can broadly neutralize SARSCoV2 Variants of Concerns (VOCs) including Alpha, Beta, Gamma, Delta and Omicron. - Antikörper

Product Properties

• Tag: Human IgG1 | Human Kappa
• Buffer: PBS, pH7.4
• Purity: 0.95
• Form: Powder
• Target: Spike RBD

Images

Detection of Anti-SARS-CoV-2 Spike RBD Broadly Neutralizing Antibody, Human IgG1 (MALS verified) titer by compitive-ELISA Assay. Serial dilutions of Anti-SARS-CoV-2 Spike RBD Broadly Neutralizing Antibody, Human IgG1 (AM359b) (Cat. No. SPD-M265) were added into Human ACE2 / ACEH Protein, Fc Tag (Cat. No. AC2-H5257): HRP-SARS-CoV-2 Spike RBD, His Tag (B.1.1.529/Omicron) binding reactions. The half maximal inhibitory concentration (IC50) is 0.1578 µg/mL (QC tested).

Anti-SARS-CoV-2 Spike RBD Broadly Neutralizing Antibody, Human IgG1 (AM359b) (Cat.No. SPD-M265) neutralizes SARS-CoV-2 Spike RBD by inhibiting RBD: ACE2 interaction. The ACE2-coated plate is incubated with the wild type (WT) RBD or B.1.1.7, B.1.351, P.1, B.1.617.2, B.1.1.529 mutant and treated with the neutralizing antibody at increasing concentration. Percent inhibition is calculated based on the OD value.

Anti-SARS-CoV-2 Spike RBD Broadly Neutralizing Antibody, Human IgG1 (AM359b) on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 0.95.